Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial
The study failed to meet its primary end point of ORR. DDR and homologous recombination repair defects are not consistently actionable with olaparib as monotherapy or in combination with other targeted therapies in a histology-agnostic manner.
Authors
- Jacqueline Moses (ORCID: https://orcid.org/0000-0001-9128-4202)
- Navid Hafez (ORCID: https://orcid.org/0000-0001-8115-9328)
- Peter G. Mortimer (ORCID: https://orcid.org/0000-0003-2900-2336)
- Deborah B. Doroshow (ORCID: https://orcid.org/0000-0002-2221-9818)
- Jeffrey Sklar (ORCID: https://orcid.org/0000-0001-5334-6070)
- Colin P. Glover
- Joseph P. Eder (ORCID: https://orcid.org/0000-0002-7805-0986)
- H. Mahdi
- Patricia LoRusso (ORCID: https://orcid.org/0000-0001-7144-036X)
- Davendra Sohal (ORCID: https://orcid.org/0000-0002-0182-8403)
- Vicki L. Keedy (ORCID: https://orcid.org/0000-0002-7213-7562)
- Juliane M. Jürgensmeier (ORCID: https://orcid.org/0000-0001-8438-2429)
- Michael Cecchini
- Khanh Do
- Geoffrey I. Shapiro
Institutions
- Cleveland Clinic (US)
- Vanderbilt University (US)
- Yale Cancer Center (US)
- AstraZeneca (Brazil) (BR)
- Dana-Farber Cancer Institute (US)
- University of Pittsburgh Medical Center (US)
- Vanderbilt-Ingram Cancer Center
Publication Details
- Journal
- Cancer
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1002/cncr.70332
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00